A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial Evaluating the Efficacy and Safety of Mecasin (KCHO-1) in Adults with Amyotrophic Lateral Sclerosis
Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive muscle weakness and paralysis, with respiratory failure being the leading cause of death. Mecasin (KCHO-1), a standardized botanical extract, has demonstrated neuroprotective and anti-neuroinflammatory effects in preclinical studies. A 12-week phase IIa trial suggested a potential benefit in slowing functional decline. This phase IIb trial evaluated the efficacy and safety of Mecasin over 24 weeks, including respiratory-related outcomes. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, 50 patients were randomized to receive Mecasin (2.4 g/day) or placebo for 24 weeks, with both groups receiving riluzole (100 mg/day). Forty-three patients were included in the efficacy analysis. The primary endpoint was change in the Korean version of the ALS Functional Rating Scale-Revised (K-ALSFRS-R) total score. Respiratory-related assessments included orthopnea, FEV1/FVC, and end-tidal CO2, alongside safety evaluations. Results: At week 24, K-ALSFRS-R changes were −3.65 and −3.74 points in the Mecasin and placebo groups, respectively, with no significant between-group difference (estimated difference, 0.27; 90% CI, −1.80 to 2.33; p = 0.4146). Significant between-group differences were observed in FEV1/FVC (7.69 percentage points; p = 0.0036) and end-tidal CO2 (−3.92 mmHg; p = 0.0076). Linear mixed-effects models showed significant group-by-visit interactions for orthopnea (p = 0.0212) and FEV1/FVC (p = 0.0228). Adverse-event frequencies were comparable. Conclusions: Although Mecasin did not show a significant effect on the primary outcome (K-ALSFRS-R total score), the observed differences in respiratory-related outcomes provide a clinical rationale for further investigation in larger trials focusing on respiratory function.
Authors
- Eunhye Cha
- Hyung-Won Kang (ORCID: https://orcid.org/0000-0001-6497-0100)
- Bong-Keun Song
- Joonyoung Shin (ORCID: https://orcid.org/0000-0002-5064-6227)
- Sungchul Kim (ORCID: https://orcid.org/0009-0002-9513-0758)
- Boncho Uk Ku (ORCID: https://orcid.org/0000-0001-5520-9782)
- Ilhong Son (ORCID: https://orcid.org/0000-0001-9038-1369)
- Wookcheol Seo (ORCID: https://orcid.org/0000-0003-0397-6466)
- Dongwoon Han (ORCID: https://orcid.org/0000-0003-0206-8976)
- Taeseong Jeong (ORCID: https://orcid.org/0000-0002-2822-5784)
- Dongwoung Kim
- Hyorin Lee
Institutions
- Kwangju Christian Hospital (KR)
- Korea Institute of Oriental Medicine (KR)
- Wonkwang University Sanbon Hospital (KR)
- Hanyang University (KR)
- Wonkwang University (KR)
- Gwangju University (KR)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/jcm15229076
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00